Recently, two novel SMO inhibitors, based on Vismodegib (GDC-0449), decreased Ptch+/−/p53−/− MB allograft tumour growth [15], however further investigations are required before a possible clinical trial. This evidence concerns the gene PTCH1 and neoplasm.